XRCC1 and Patent ductus arteriosus: While there are currently no known XRCC1 inhibitors, we wondered whether XRCC1 expression was decreased (a genetic vulnerability) in PDA tissue vs associated normal pancreas tissue in patient samples, as noted in head and neck cancers33, 34, 35.